-
Haematologica Jul 2021
Topics: Burkitt Lymphoma; Central Nervous System; Humans
PubMed: 33538157
DOI: 10.3324/haematol.2020.278181 -
Clinical Advances in Hematology &... Dec 2018Burkitt lymphoma (BL) is a highly aggressive B-cell non-Hodgkin lymphoma characterized by marked tumor proliferation resulting from translocation of the MYC oncogene.... (Review)
Review
Burkitt lymphoma (BL) is a highly aggressive B-cell non-Hodgkin lymphoma characterized by marked tumor proliferation resulting from translocation of the MYC oncogene. Distinct clinical variants include endemic, sporadic, and immunodeficiency-associated cases. All variants are characterized by rapidly dividing tumor masses that quickly disseminate to extranodal sites, including the bone marrow and central nervous system (CNS). Although common in children, BL is rare in adults, mandating a high index of clinical suspicion for timely diagnosis. Prompt recognition and initiation of comprehensive supportive care are essential for prevention of early complications, such as tumor lysis syndrome and multisystem organ dysfunction. BL is highly sensitive to chemotherapy, and patients who tolerate highly intensive combination chemotherapy regimens are frequently cured. Most regimens were developed in children and young adults, however, and the treatment-related toxicities remain a major barrier for those with advanced age and/or comorbid conditions. Younger patients are less susceptible to acute toxicities but are more likely to experience long-term sequelae of treatment, including infertility and secondary malignancies. The infusional regimen of dose-adjusted etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, and regular- or double-dose rituximab (DA-EPOCH-R or -RR) is less toxic than standard BL regimens, yet maintains high rates of cure across a diverse range of patients, including those with disseminated disease, advanced age, and HIV infection. Patients with low-risk BL can be cured with just 3 cycles of DA-EPOCH-RR. Still, patients with CNS involvement remain at high risk for early death, and prevention of late CNS relapses remains a priority. Future studies combining rational targeted agents with DA-EPOCH-R or -RR may further improve the cure rate.
Topics: Adult; Age Factors; Burkitt Lymphoma; Disease Management; Humans
PubMed: 30843890
DOI: No ID Found -
British Dental Journal May 2023
Topics: Humans; Burkitt Lymphoma; Toothache
PubMed: 37237183
DOI: 10.1038/s41415-023-5925-3 -
Clinical Lymphoma Jun 2005Burkitt's lymphoma is a mature B-cell lymphoma that is characterized by a rapid proliferative rate and propensity for extranodal sites of involvement such as the... (Review)
Review
Burkitt's lymphoma is a mature B-cell lymphoma that is characterized by a rapid proliferative rate and propensity for extranodal sites of involvement such as the gastrointestinal tract and central nervous system. This subtype of non-Hodgkin's lymphoma is associated with unique cytogenetic translocations involving the c-MYC oncogene on chromosome 8, which appears to be involved in the pathogenesis of this disease. Although current literature is limited by a lack of randomized trials, Burkitt's lymphoma appears to be curable in a high proportion of cases if treated with aggressive multiagent chemotherapy regimens. The use of autologous stem cell transplantation appears to benefit patients who have had chemotherapy-sensitive relapses. The role of allogeneic stem cell transplantation for this disease remains uncertain. Patients with HIV-associated Burkitt's lymphoma appear to have a better prognosis today, which is likely a result of more effective antiretroviral therapy and the ability to treat selected patients with more aggressive chemotherapeutic regimens than before. This article will review the epidemiologic, biologic, diagnostic, and therapeutic aspects of Burkitt's lymphoma in adults.
Topics: Adult; Burkitt Lymphoma; Humans
PubMed: 15989701
DOI: 10.3816/clm.2005.n.021 -
Pediatrics International : Official... Feb 2021
Topics: Burkitt Lymphoma; Humans; Kidney
PubMed: 33629426
DOI: 10.1111/ped.14485 -
Proceedings of the Royal Society of... Sep 1971
Review
Topics: Africa; Burkitt Lymphoma; Hemoglobinopathies; Herpesvirus 4, Human; Humans; Infectious Mononucleosis; Insect Vectors; Malaria; New Guinea; Tropical Climate; Viral Vaccines
PubMed: 4329792
DOI: No ID Found -
East African Medical Journal Aug 2004To put together salient historical, geographical and biological characteristics of Burkitt's lymphoma. (Review)
Review
OBJECTIVES
To put together salient historical, geographical and biological characteristics of Burkitt's lymphoma.
DATA SOURCES
Burkitt's lymphoma study data gathered over a ten year study, other publications, original and review articles, conference abstracts searched mainly on PubMed indexed for Medline.
DATA EXTRACTION
A systematic documentation and review to identify information relating to Burkitt's lymphoma, historical, geographical and biological characteristics. Only data relevant to the objectives of the subject were extracted.
DATA SYNTHESIS
A detailed qualitative assessment was undertaken given the heterogeneity of data and study types making it not appropriate to pool results across studies.
CONCLUSION
Burkitt's lymphoma is historically linked to the tropical Africa and its geographical characteristics have been the most defining characteristics of its other features. The biological characteristic also roots strongly in its geographical and clinical manifestations.
Topics: Burkitt Lymphoma; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Humans; Translocation, Genetic; Tropical Climate
PubMed: 15622604
DOI: 10.4314/eamj.v81i8.9209 -
Cancer Research May 1974
Review
Topics: Animals; Antigens, Neoplasm; Antigens, Viral; Burkitt Lymphoma; Cell Line; Chromium Radioisotopes; Culture Techniques; Cytotoxicity Tests, Immunologic; Herpesvirus 4, Human; Hodgkin Disease; Humans; Hypersensitivity, Delayed; Immunity, Cellular; Leukemia; Lymphoma; Mice; Neoplasms, Experimental
PubMed: 4366992
DOI: No ID Found -
Current Opinion in Hematology Jul 2007Burkitt's lymphoma is a unique hematological malignancy remarkable for its biological characteristics, including aberrant expression of the MYC oncogene, and its... (Review)
Review
PURPOSE OF REVIEW
Burkitt's lymphoma is a unique hematological malignancy remarkable for its biological characteristics, including aberrant expression of the MYC oncogene, and its requirement for intensive treatment regimens. This review will focus on those features, and discuss recent advances in the molecular biology and advancing treatment options for the disease.
RECENT FINDINGS
Advances in molecular biology have provided many new insights into the biology and treatment options for Burkitt's lymphoma. Microarray technology has recently been used to define a molecular gene expression signature for Burkitt's lymphoma. This signature allows for the differentiation of Burkitt's lymphoma from other forms of non-Hodgkin's lymphoma such as diffuse large B-cell lymphoma. Recent advances in the use of biological agents, such as rituximab, have also allowed for a reduction in treatment toxicities while still offering comparable survival outcomes for patients.
SUMMARY
Burkitt's lymphoma is an interesting mature B-cell non-Hodgkin's lymphoma that has numerous distinct features and clinical variants depending on factors such as geographical location, immunological status and patient's age. Although the role of the MYC oncogene has been well studied, we are only now appreciating the defining molecular characteristics of this disease, and using these advances to improve treatment options for patients.
Topics: Antineoplastic Agents; Burkitt Lymphoma; Genes, myc; Hematopoietic Stem Cell Transplantation; Humans; Molecular Biology; Treatment Outcome
PubMed: 17534164
DOI: 10.1097/MOH.0b013e3281bccdee -
Journal of Medicine 1981Clinical and epidemiologic features of Burkitt's lymphoma are reviewed. Epidemiologic studies suggest that simultaneous infection with Epstein-Barr (E-B) virus and... (Review)
Review
Clinical and epidemiologic features of Burkitt's lymphoma are reviewed. Epidemiologic studies suggest that simultaneous infection with Epstein-Barr (E-B) virus and malaria may be involved as etiologic agents. On the other hand we have found that in the Amazon region of Brazil and Peru both malaria and E-B virus infection is common among children, yet Burkitt's lymphoma is rare. The possibility exists that other concomitant etiologic agents and genetic factors are also involved. Several investigators suggested the possible involvement of Reo 3 virus. We have found antibodies against Yaba virus. A laboratory worker who accidentally inoculated himself with Yaba virus developed a histiocytoma which when inoculated into Asiatic monkeys produced typical Yaba tumors. This was the first case that Koch's postulates were fulfilled in a virus induced neoplasm in man. Therapeutically, the best clinical results were obtained in those patients who were treated with small doses of cyclophosphamide. On the basis of somewhat inadequate follow-up studies, it is estimated that "five year cures" were obtained in about 10% of the patients.
Topics: Adolescent; Adult; Africa; Aged; Aging; Animals; Burkitt Lymphoma; Humans; Middle Aged; Yaba monkey tumor virus
PubMed: 6274988
DOI: No ID Found